In Hep3B and other HCC cell lines, DR4 is targeted by Mir-106b, and Mir-106b inhibitors can induce increased DR4 expression and enhance TRAIL-mediated HCC apoptosis (Xu et al., 2017). The gene discussed is TNFRSF10A; the disease is hepatocellular carcinoma.